13 Sep 2024 | 10:01 AM UTC
CAR: Confirmed dengue fever cases reported in multiple areas in Bangui in September
Confirmed dengue fever cases reported in multiple areas in Bangui, Central African Republic, in September. Avoid mosquito bites.
Health authorities have reported confirmed dengue fever cases in Bangui, with 13 confirmed cases reported as of Sept. 10. The Central African Republic (CAR) reported its first dengue fever case in 2023 when one case was identified in Bambari. Health districts reporting cases include Bangui 1, 2, and 3, and Bimbo. The CAR’s Ministry of Health and Population has already taken the necessary preventive measures to prevent the rapid spread of the disease throughout the country. Preventive measures include free screening services, self-isolation of identified cases, and hospitalization of severe cases. This report represents the most complete data available as of Sept. 13.
If you have previously been infected with dengue fever, consult with your physician regarding vaccination. Avoid mosquito bites and remove standing water to reduce the number of biting mosquitoes. Seek medical attention if symptoms develop within two weeks of being in affected areas. Do not use aspirin or ibuprofen products if dengue fever is suspected, as these could exacerbate bleeding tendencies associated with the disease.
Dengue fever is transmitted through the bite of an infected mosquito. Risk of infection is often highest in urban and semi-urban areas. Symptoms of dengue fever include a sudden onset of fever and at least one of the following: severe headache, severe pain behind the eyes, muscle and/or joint pain, rash, easy bruising, and/or nose or gum bleeding. Symptoms typically appear 5-7 days after being bitten, but can develop up to 10 days after exposure. Dengue fever can progress to a more severe form known as dengue hemorrhagic fever (DHF). DHF can be fatal if it is not recognized and treated in a timely manner. There are two dengue fever vaccines, Dengvaxia (CYD-TDV) and Qdenga (TAK-003). Dengvaxia is only recommended for individuals with a history of dengue infection and who live in dengue-endemic countries or areas. Qdenga is recommended for children aged 6-16 in settings with high dengue burden and transmission intensity. Check with your healthcare provider if dengue vaccination is needed.
